Blair William & Co. IL Decreases Position in Cellebrite DI Ltd. $CLBT

Key Points

• Blair William & Co. IL has reduced its stake in Cellebrite DI Ltd. by 27.6%, selling 32,855 shares, leaving it with 86,027 shares valued at approximately $1.38 million.
• In recent quarter earnings, Cellebrite DI reported $0.12 earnings per share, exceeding analyst estimates of $0.11, with a year-over-year revenue increase of 18.4% to $113.28 million.
• Analysts have mixed views on the stock, with four maintaining a Buy rating and one issuing a Sell rating, and a consensus price target of $21.75.

Blair William & Co. IL lessened its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 27.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,027 shares of the company's stock after selling 32,855 shares during the quarter. Blair William & Co. IL's holdings in Cellebrite DI were worth $1,376,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC lifted its stake in shares of Cellebrite DI by 2.5% in the first quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after buying an additional 688 shares in the last quarter. Signaturefd LLC lifted its stake in shares of Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company's stock worth $32,000 after buying an additional 819 shares in the last quarter. Bosun Asset Management LLC lifted its stake in shares of Cellebrite DI by 2.5% in the first quarter. Bosun Asset Management LLC now owns 44,376 shares of the company's stock worth $862,000 after buying an additional 1,069 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Cellebrite DI by 24.7% in the first quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock worth $119,000 after buying an additional 1,214 shares in the last quarter. Finally, Assetmark Inc. bought a new position in shares of Cellebrite DI in the first quarter worth approximately $33,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $19.30 on Thursday. The firm has a fifty day moving average price of $17.06 and a 200-day moving average price of $16.96. The stock has a market cap of $4.62 billion, a PE ratio of -25.39, a price-to-earnings-growth ratio of 3.53 and a beta of 1.29. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same quarter in the prior year, the business earned $0.10 earnings per share. Cellebrite DI's revenue for the quarter was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CLBT shares. Lake Street Capital lowered their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Friday, September 26th. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an "overweight" rating in a report on Wednesday, September 24th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Cellebrite DI in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $21.75.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.